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Abstract 18 
Genotype E of small ruminant lentivirus has been recently described in goats from different breeds 19 
in Italy. Genotype E infection may differ from known genotypes since deletions of dUTPase and 20 
VPR proteins have been confirmed in different independent areas and goat breed, and play a key 21 
role on virus replication and pathogenesis. In particular, genotype E Roccaverano strain has been 22 
described as low pathogenic since does not lead to clinical symptoms in goats. In contrast, classical 23 
CAEV infected goats of the same area and breed presented arthritis. In this study, we have used 24 
intratracheal and intra-bone marrow routes to establish genotype E persistent infections. Humoral 25 
and cellular immune responses elicited in the host against genotype E and genotype B derived 26 
antigens were evaluated until 200 days post-inoculation. Compared to genotype B antigen, 27 
seroconversion against genotype E GAG p16-25 antigen was detected at 2-3 weeks after 28 
inoculation, significantly earlier and at higher titres. Interestingly, antibody avidity did not increase 29 
in the course of the experiment neither against p16-25 nor against SU5, both derived from genotype 30 
E.  31 
T cell proliferation against p25-GST fusion protein antigens derived from genotype E was firstly 32 
detected at 15 days post-inoculation and was maintained throughout time until week 20 post 33 
infection, while T cell proliferation against the genotype B p25 was not produced by the end of the 34 
experiment at 20 weeks post-inoculation. The strengh of reaction was also higher when using p25 E 35 
as stimulator antigen. T cell responses against P25 E.  36 
In contrast with antibody and T cell proliferation, cytotoxic-T-lymphocyte (CTL) activity in the 37 
circulating lymphocytes (effector cells) using blood-derived macrophages (BDM) as target cells, 38 
was not strain specific being surprisingly higher against genotype B infected antigen presenting 39 
cells (APCs). 40 
This is the first study reporting experimentally induced immunological changes in SRLV genotype 41 
E infection and indicates that CTL activity may be the adaptive immune response able to induce 42 
protection against heterologous infection.  43 
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Introduction 44 
Small ruminant lentiviruses (SRLV), including Visna/Maedi virus (VMV) and Caprine Arthritis 45 
Encefalitis virus (CAEV), are genetically and antigenically a heterogeneous group of viruses that 46 
infect sheep and goats causing chronic inflammation in the lungs, udder, carpal joints and central 47 
nervous system. Five genotypes from A to E have been described in different countries (Gjerset et 48 
al., 2007; Glaria et al., 2009; Grego et al., 2007; Pisoni et al., 2005; Shah et al., 2004), with an 49 
apparent correspondence between genetic background and clinical form. For example, genotype A2 50 
sequences are from neurotropic strains causing Visna (Haflidadottir et al., 2008), genotypes B1 and 51 
B2 are mainly associated to arthritis in goats (Pisoni et al., 2005) and sheep (Glaria et al., 2009; 52 
Rosati et al., 2004), respectively. Roccaverano strain (subtype E1) has been described as a low 53 
pathogenic strain within genotype E, since it lacks the entire dUTPase and Vpr-like genes and no 54 
clinical symptoms including arthritis have been recorded in animals after years of natural infection 55 
(Reina et al., 2009a). Furthermore, artificial deletions of these genes in a CAEV-Co backbone 56 
resulted in delayed viral replication, accumulation of G to A mutations and decreased proviral load 57 
and lesion development in the inoculated animals (Harmache et al., 1996; Turelli et al., 1997). 58 
Moreover, in herds with naturally co-infected animals (mainly with subtype B1 and E1) gag-PCR 59 
(using universal primers) frequently detected only genotype E sequences, suggesting a higher 60 
proviral load of the latter genotype. Lesion development was also unnoticed in these animals, in 61 
contrast with those of the same area and breed only infected with B1 subtype (Grego et al., 2007; 62 
Reina et al., 2009a). These observations, together with the increasing interest in the last decades for 63 
the development of live attenuated viruses able to induce resistance to superinfection, prompted us 64 
to characterize in genotype E infections both humoral and cellular early immune responses. In this 65 
work we evaluated antibody response, T cell proliferation and cytotoxic-T-lymphocyte (CTL) 66 
activity using homologous and heterologous antigens in animals experimentally infected with 67 
genotype E. Results demonstrate that after inoculation antibody response and T cell proliferation 68 
responses were elicited exclusively against E1 subtype, and not B1 antigen. However, CTL activity 69 
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against target cells infected with B1 isolate was detected 15 weeks post-inoculation (p.i.), which 70 
might be associated with protection to superinfection versus heterologous lentivirus strains.  71 
 72 
Materials and methods 73 
Viral strains 74 
Subtype E1 strain Roccaverano (prototype of genotype E), recently isolated and sequenced (Reina 75 
et al., 2009a) was used in this study for the experimental infection and CTL assays. CAEV-TO1/89 a 76 
subtype B1 strain also characterized in previous studies (Grego et al., 2002) was used for in vitro 77 
CTL assay as a conventional CAEV-like strain. 78 
Strain Roccaverano was grown and titrated using blood derived macrophages (BDM) and 79 
immunocytochemistry as described (Juganaru et al 2010, unpublished results) since this strain does 80 
not efficiently replicate in caprine fibroblastic cells. Virus was stored in aliquots at -80°C until used. 81 
The same viral stock was employed in experimental infection and CTL assays. 82 
 83 
Experimental infection of goats 84 
Animals (breeding stock) from a certified SRLV-free herd of Roccaverano breed goats were used in 85 
this study. They were purchased as weaned kids and introduced into the experimental facilities at 86 
the Faculty of Veterinary Medicine, University of Turin, Grugliasco (CISRA_FMV_UNITO) at 87 
least 18 months before the experimental infection. Animals were tested monthly and found 88 
consistently negative for SRLV antibodies using genotype A, B and E-derived antigens. In order to 89 
determine the optimal infectious dose and the route of inoculation, we conducted a first pilot 90 
experimental infection study using 4 animals of 8 months of age, two of which were inoculated 91 
intra-tracheally and two by injection into the trochanteric fossa. For each route, two different doses 92 
were used (10
5
 TCID50/ml and 10
6
 TCID50/ml). According to the results obtained, we carried out a 93 
second experimental infection study involving 8 animals inoculated intra-tracheally with 2 ml of 94 
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2.5X10
5
 TCID50/ml. Nine goats were used as a negative control group. Animals included in the 95 
experimental and control groups had similar age distribution, ranging from 9 to 24 months.  96 
Experiments were carried out in compliance with the relevant national legislation on experimental 97 
animals and animal welfare, upon authorization by the competent authority (Italian Ministry of 98 
Health-Directorate General Animal Health-Office VI; permit n. 07/2009B).  99 
 100 
Sampling 101 
Pilot experiment 102 
Blood samples were collected in K3-EDTA tubes, 15 days prior to infection (-15), and at days 0, 7, 103 
14, 21, 28, 35, 42, 49, 63, 77, 107, 129, 157 and 177 days p.i.. 104 
After centrifugation at 800 g for 20 minutes, plasma was stored at -20°C for ELISA analysis. After 105 
seroconversion, an additional EDTA-blood sample was obtained in order to isolate peripheral blood 106 
mononuclear cells (PBMCs) on a Ficoll gradient (δ=1.077; Lymphoprep®) for use in proliferation 107 
and CTL assays.  108 
Second experimental infection study 109 
Blood samples from the 8 infected goats were collected in the same manner at regular intervals -15, 110 
7, 14, 21, 28, 35, 42, 49, 63, 77, 91, 104, 118 and 132 dpi. Plasma was stored at -20ºC for ELISA 111 
determinations. Additional EDTA-blood samples were obtained before immunization and also 2, 4, 112 
8 and 20 weeks p.i. for T ell proliferation and at 15 weeks p.i. for CTL assays. PBMCs were 113 
obtained as described in the pilot experiment.  114 
 115 
Measurement of group-specific antibodies in plasma 116 
Seroconversion was evaluated using an indirect ELISA based on homologous and heterologous 117 
matrix and capsid recombinant fusion proteins (P16-25 from genotypes E and B, respectively) 118 
obtained as previously described (Reina et al., 2009b). Additionally, type specific antibodies against 119 
E antigen were detected by an ELISA using SU5 synthetic peptide as coating antigen corresponding 120 
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to the 24 amino acids QVRAYTYGVIEMPTGYETPTIRRR from Roccaverano strain. Both 121 
recombinant and synthetic ELISA procedures have been described in details in previous works 122 
(Reina et al., 2009b; Carrozza et al., 2009). Results were expressed as percentage of reactivity of 123 
each sample vs positive control serum enclosed in each plate. Samples were considered positive 124 
when reactivity was above 40% absorbance of positive control.  125 
 126 
Antibody avidity measurements  127 
Antibody avidity index was determined for both E-derived antigens (P16-25 and SU5) at different 128 
time points from 3 to 25 weeks p.i. by testing the stability of the antigen-antibody complexes 129 
following an additional washing step with 8M urea as described (Mordasini et al., 2006). Samples 130 
with avidity indexes <30% were considered to be of low avidity. 131 
 132 
T cell proliferation assay 133 
Measurement of T cell proliferation against homologous and heterologous antigens was carried out 134 
as described elsewhere (de Andres et al., 2009; Niesalla et al., 2009; Reina et al., 2008). Briefly, 135 
PBMCs were plated in 96-well plates at a concentration of 10
5 
cells/well and incubated in 136 
quadruplicate with recombinant heterologus (genotype B) or autologus (genotype E) GST/P25 137 
fusion protein, or GST (as negative control) at equimolar amounts. Antigens were plated at 25, 12 138 
and 6 µg/ml in 200 µl. After a five-day incubation, cells were labelled with 1 µCi of [
3
H] thymidine
 139 
(Amersham) for 5 h; incorporated radioactivity was determined using a Filter Cell Harvester 1540 140 
(Wallac) and a Beta counter. Proliferation was measured as a stimulation index (SI) normalizing 141 
incorporated radioactivity in P25 wells with that obtained in the GST wells. The SI was calculated 142 
for each antigen using the formula SI = cpm with antigen/cpm with GST protein. 143 
An individual animal was considered to show positive T cell reactivity if the SI was greater than 3 144 
in at least two antigen dilutions. 145 
 146 
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CTL assay 147 
Due to a reduced replication of Roccaverano strain in fibroblastic cell lines, we used BDM as live 148 
viral antigen presenting cells (APC) and as target cells as described (Lee et al., 1994) with minor 149 
modifications. Briefly, BDM were cultured on 24-well plates for 10 days in differentiating medium 150 
RPMI 10%-goat serum further supplemented with vitamins, 100 U penicillin, 100 µg 151 
streptomycin/ml, β-mercaptoethanol (50µM), 2 mM L-glutamine and non-essential aminoacids 152 
(Sigma–Aldrich Company Ltd), and used from days 11 to 30. 153 
On day 11 BDM were infected with Roccaverano strain at a MOI of 1, based on approximate in situ 154 
cell count. Three days later 2x10
6
 autologous PBMCs were added and medium replaced with 155 
RPMI-10% FCS and 5U/ml recombinant human Interleukin 2 (r-Hu IL2; Sigma–Aldrich Company 156 
Ltd). After 7 days, viable lymphocytes were transferred to new BDM infected three days before 157 
with Roccaverano strain at a MOI of 1 and incubated for additional 7 days. Viable lymphocytes 158 
were collected, at the end of the two proliferation steps and added as effector cells to newly 159 
autologous or heterologous BDM, each of them separately infected with either Roccaverano strain 160 
(72 h after infection) or CAEV-TO1/89 isolate (48 h after infection). Different effector to target 161 
ratios were performed. After 16 h, target cells were washed with PBS and lysed in 100 µl lysis 162 
buffer (25mM Hepes, 5 mM EGTA, 1mM EDTA, 5mM MgCl2, CHAPS 1%, 5mM DTT) with 163 
protease inhibitors cocktail (Sigma–Aldrich Company Ltd) and stored at -80ºC. Positive control for 164 
caspase activity was performed in replica wells in the presence of 1 µM staurosporine (Sigma–165 
Aldrich Company Ltd). 166 
To measure the CTL-induced caspase 3 activation within target cells, expression of caspase 3 was 167 
assayed by monitoring the production of 7-amino-4-methylcoumarin (AMC) from a specific 168 
fluorogenic peptide Ac-DEVD-AMC  (BACHEM, Bubendorf, Switzerland) used at a final 169 
concentration of 100 μM in 25 mM Hepes pH 7.5, 10 mM DTT, 10% sucrose, 1% CHAPS. 170 
Reactions were started by adding an aliquot of sample, and the fluorescence of released AMC 171 
(excitation, 380 nm; emission, 460 nm) was monitored continuously at 37°C with a Carry Eclipse 172 
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spectrofluorimeter (VARIAN, Palo Alto, CA). Results were expressed as nmol of cleaved 173 
peptide/mg*min and specific CTL activity was calculated for each strain by the following formula: 174 
infected minus mock infected autologous cells divided by infected minus mock infected 175 
heterologous cells. CTL activity cutoff was determined in 9 SRLV free animals, used as negative 176 
control, as the mean CTL activity of negative controls plus 3 times standard deviation (SD). In vitro 177 
positive control consisted in applying the same protocol using BDM derived from 2 goats naturally 178 
infected with a field subtype B1 isolate.  179 
 180 
Statistical analyses 181 
Differences in seroconversion comparing ELISA absorbance values were evaluated using Wilcoxon 182 
paired-sample test. T cell proliferation mean S.I. values were compared in immunized and control 183 
group animals using Wilcoxon’s paired-sample test. In order to use SD in CTL assay cutoff 184 
determination, normal distribution of CTL activity values was assessed using Shapiro Wilk’s test. 185 
All statistical analyses were conducted using R software (R Development Core Team; 186 
http://www.R-project.org). 187 
 188 
Results  189 
Antibody response  190 
Pilot experimental infection, using two different sites of injection in 4 animals, was assayed during 191 
6 months. Seroconversion was evaluated with a recombinant P16-P25-ELISA specific for genotype 192 
E, in order to establish the dose and the efficient injection route causing persistent infection. Time 193 
of seroconversion in these 4 goats was independent from the route of infection and slightly delayed 194 
in animals receiving the lower (10
5
 TCID50) viral dose. Seroconversion was achieved within 2-3 195 
weeks p.i. using the higher dose (10
6
 TCID50) while the two animals receiving the lower dose 196 
seroconverted within 4 and 14 weeks p.i..  197 
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The second experimental infection study (n=8) was carried out using an intermediate dose (5x10
5
 198 
TCID50) and the intratracheal route, which was more practical and reproducible. All the inoculated 199 
subjects seroconverted against homologous P16-25 within 14 and 107 days p.i. (Fig 1). Absorbance 200 
distribution reached a first pick around 50 days p.i. and a second one between 90 – 107 days p.i. 201 
leading to a persistent antibody response specifically mounted against genotype E antigen. On the 202 
other hand, reactivity against genotype B derived antigen was quite low, reaching in few cases the 203 
positivity threshold. Thus, ELISA test based on recombinant P16-25 derived from genotypes B and 204 
E clearly indicate that seroconversion against homologous antigen was detected well in advance as 205 
regards heterologous antigen (Fig. 1, Wilcoxon’s paired-sample test p < 0.05 from 15 to 131 days 206 
p.i.). 207 
Antibody response against SU5 peptide of genotype E was also consistently detected through time 208 
and showed an absorbance distribution comparable to that obtained using the recombinant P16-25 209 
(Fig. 2). All control goats remained negative throughout the experiment to all ELISA tests applied 210 
(data not shown). 211 
 212 
Avidity maturation of antibodies to P16-25 and SU5 213 
To explore the possibility of antibody maturation in terms of avidity changes, we performed an 214 
alternative ELISA protocol including an additional washing step with urea 8 M using only the 4 215 
immunized goats of the pilot experiment. Considering the cut-off in avidity evaluation (30%), no 216 
changes in antibody avidity were observed during the whole experiment neither versus P16-25 217 
(maximum avidity 10.27%) nor against SU5 antigens maximum avidity 5.29%. 218 
 219 
T cell proliferative responses  220 
After seroconversion, cellular immune response was first evaluated in the pilot experiment (n=4) 221 
using P25 and P16-25, both antigens derived from genotype E. Reactivity was found in 3 out of 4 222 
animals against both GAG antigens. However, P25 was chosen in subsequent assays as the 223 
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stimulating antigen, since recombinant protein production was much more efficient than in the case 224 
of P16-25 in terms of yield and solubility. In a further step P25 from genotype B was obtained, but 225 
in this case reactivity was not found in any of the four animals, although it was high in naturally 226 
infected goats with genotype B (data not shown). Proliferations appeared to be higher using the 227 
homologous antigen compared with the heterologous one in terms of frequency of positive animals 228 
as well as in strength of reaction (SI values). There were no substantial differences among routes of 229 
infection although dose was determinant in inducing strong T cell responses. Animals receiving the 230 
highest dose appeared to yield increased SI values, although statistical analyses were not conducted 231 
due to limited number of animals (n=4).  232 
As expected, basal T cell reactivity (day -15) in animals from the second experimental infection 233 
experiment (n=8) was quite low since animals belonged to a long term seronegative flock (Fig 3) 234 
where none of the animals showed a positive proliferation neither against P25E nor against P25B. 235 
Positive animals were firstly detected by 2 weeks p.i., and reached a maximum by week 20 with 236 
50% of the animals reacting against P25E. In the whole experiment no animal showed positive 237 
proliferation against P25B. 238 
In terms of strength of reaction, P25E induced stronger reactions than P25B from weeks 4 to 20 239 
(Fig 3), with SI values in positive animals ranging from 3.37 to 53.14 likely showing the normal 240 
variation in virus-specific recall responses in this outbred goat population. A significant increase in 241 
SI obtained using P25E was observed between 8 and 20 weeks after experimental inoculation (Fig. 242 
3). 243 
 244 
Cytotoxic T cell responses 245 
Next, we determined if lymphocytes from Roccaverano infected goats, stimulated in vitro with 246 
Roccaverano live virus, had a CTL activity against target cells infected with genotype E or B. For 247 
this purpose, BDM target cells were tested for caspase 3 activity induced by CTL effectors from 248 
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infected (n=8) and uninfected (n=9) goats after two stimulation cycles with genotype E virus, and 249 
live genotype E or B antigens at week 15 p.i. (Fig 4). 250 
Based on a cutoff value of 2.73 (mean CTL activity of 9 uninfected goat plus 3XSD, Shapiro-251 
Wilk’s normality test W = 0.96, p = 0.7276), three of the infected goats (37.5%) had a high CTL 252 
activity against heterologous strain with an average CTL value of 7.42 in infected group. 253 
Surprisingly, no CTL activity was detected against BDM infected with the homologous strain 254 
Roccaverano. The uninfectec group of goats had no CTL activity against the E or B infected cells. 255 
The two CAEV-B1 naturally infected goats showed a CTL activity against CAEV-infected BDM, 256 
although it was  close to the cut-off value (Fig. 4). 257 
 258 
Discussion  259 
This study describes early immunological changes observed upon experimental infection of goats 260 
with low pathogenic SRLV strain Roccaverano belonging to genotype E, aiming to provide 261 
evidence of a potential cross-protective adaptive response in infected animals.  262 
Several studies have tested different routes of infection for genotypes A and B being the 263 
intratracheal the most used infection route (McNeilly et al., 2007; Torsteinsdottir et al., 2003; 264 
McNeilly et al., 2008) with few disadvantages compared to intranasal, conjunctival space, intra 265 
pulmonary and endovenous routes (Begara et al., 1996; Niesalla et al., 2008; Torsteinsdottir et al., 266 
2003). In the pilot experiment, we used for the first time the direct inoculation of the infectious dose 267 
in the bone marrow, a reservoir of infected cells releasing infected monocytes into the blood for 268 
dissemination to target tissues (Gendelman et al., 1985), where actively replicating promonocytes 269 
could represent the necessary cellular environment for replication of dUPTase
-
 Vpr
-
 strains since 270 
intra-bone marrow inoculation of virus resulted in earlier and stronger seroconversion and T cell 271 
proliferations. However, intratracheal inoculation was finally chosen because of the easier 272 
management of the animals and consistent results.  273 
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Following experimental infection, virus showed an initial burst of replication within a few weeks, 274 
followed by an extended period of restricted replication or latency (Brahic et al., 1981; Staskus et 275 
al., 1991; Vigne et al., 1987) in which immune response switches from Th1 profile into a Th2 and 276 
finally symptoms appeared. Evidence for this switching has been shown in clinically affected 277 
animals by the production of IgG1 antibodies, together with a deficient delayed hypersensitivity 278 
reaction (Perry et al., 1995; Pyrah and Watt, 1996) and a T cell unresponsiveness abolished partially 279 
by IL-2 addition. This T cell anergy has been linked to a deficient antigenic presentation related to 280 
costimulatory molecules expression (Reina et al., 2007). 281 
Notably, in this study persistent infection assessed by seroconversion was reached in both, the pilot 282 
and the second experimental infection studies, in time intervals comparable with those described for 283 
genotypes A and B (Lacerenza et al., 2006; McNeilly et al., 2007) in spite of the restricted 284 
replication of Roccaverano strain in fibroblastic-like cells in vitro (Juganaru et al. unpublished 285 
data).  286 
Seroconversion as detected by p16-25 ELISA, was only observed against the homologous antigen, 287 
consistent with previously described results on reactivity to homologous vs heterologous antigens, 288 
involving genotypes A and B (Lacerenza et al., 2006) and genotype E under natural conditions 289 
(Reina et al., 2009b). This underlines the relevance of using the correct antigen in diagnosis.  290 
Maturation changes in antibody avidity, conformational changes and crossreactivity are strongly 291 
related to induced protection (Li et al., 2003; Nilsson et al., 1998). In this study, antibody avidity 292 
was neither increased against p16-25 from 5 to 25 weeks after infection nor against SU5 from 3 to 293 
25 weeks indicating no antibody maturation against main immunodominant epitopes. Antibody 294 
responses and protection have not been correlated so far in SRLV immunization-challenge studies. 295 
The presence of neutralizing antibodies has been linked to unprotective responses (Gonzalez et al., 296 
2005) and experiments with CAEV-inactivated vaccines, known to elicit mainly humoral response, 297 
resulted in increased lesion severity in vaccinated animals following challenge with homologous 298 
strain (McGuire et al., 1986; Russo et al., 1993). With this non-established relationship between 299 
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antibody production and broadened protection, the lack of seroconversion against heterologous 300 
antigen, may therefore not necessarily represent an immunological failure in SRLV model. 301 
Although Th1 responses have been linked to protection in lentiviral infections (Kim et al., 1999; 302 
Koup et al., 1994) a relationship between these responses and tissue damage related to TNFα 303 
production has been described (Lechner et al., 1996). Indeed, SRLV infections in which lesions are 304 
immunomediated, have led to cellular responses increasing tissue damage in vaccination-challenge 305 
experiments (Reina et al., 2008). However, genotype E infections do not lead to tissue lesions 306 
(Reina et al., 2009a). Homologous T cell proliferative responses were normal in 3 out of 4 animals 307 
in the pilot experiment and in 5 out of 8 in the second experimental infection study, which would 308 
correspond to T cell reactivity found in asymptomatic infected animals (Reina et al., 2007). 309 
Interestingly, T cell proliferative responses were entirely directed against homologous antigen and 310 
negative reactions were recorded when using genotype B reagents, suggesting a limited role of 311 
CD4+ responses in the potential protector role of genotype E infection. This is compatible with the 312 
low antibody response to genotype B strain and the antigen relatedness between genotype E and 313 
other genotypes.  314 
Cytotoxic T Lymphocytes (CTLs) are key components of the cell-mediated immune responses and 315 
play an essential role in protection against a variety of pathogens (Turner et al., 2007), including 316 
human immunodeficiency virus (HIV) and other lentiviruses (Koup et al., 1994; Letvin, 2007). 317 
Thus, CTL activity has be ome an important parameter for testing the efficacy of candidate 318 
vaccines (Deeks and Walker, 2007). SRLV-specific precursor CTL had been detected in the 319 
circulating lymphocyte pool of infected sheep (Blacklaws et al., 1994). In this study CTL response 320 
was mainly directed against genotype B and not genotype E infection, suggesting that a protective 321 
effect (if any) of Roccaverano strain against heterologous infections could reside, at least in part, in 322 
CTL acitivity. Recently CTL epitopes have been mapped in the RNase subunit of the pol gene of 323 
VMV (Wu et al., 2008). Since the corresponding region is rather conserved between Roccaverano 324 
and CAEV-like strains, with few conservative changes, this result could be expected. Thus, viral 325 
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epitopes other than P25 could explain the discrepancies in CTL and T cell proliferations observed in 326 
this and other studies (Niesalla et al., 2009).  327 
However, the observation that CTL killing of Roccaverano infected BDM was not observed at any 328 
extent was clearly unexpected. This may be explained by a deficient antigen presentation on the 329 
target cells during CTL assay since kinetics of genotype E infection on BDM is slightly protracted 330 
in vitro, compared to CAEV isolates (unpublished observation). Taking this into account, we added 331 
effector cells to CAEV and Roccaverano infected target cells at 48 h and 72 h p.i. respectively. 332 
However, this timing (72 h) for the Roccaverano infection may have not been optimal to assess 333 
CTL activity. Lack of CTL against Roccaverano is unlikely due to low antigen load in infected 334 
targets, since RT-PCR was positive at 72h post-infection (not shown). Moreover in the E-infected 335 
group, IFN- was detected in culture supernatants upon PBMC stimulation with p25 (not shown), 336 
implying an immune response involving both MHC-I and MHC-II restricted antigen presentation. 337 
Alternatively, BDM infected with Roccaverano strain may be altered, so that they escape from 338 
homologous CTL activity. In any case, special care should be taken when analyzing data on CTL 339 
killing assay since there are no studies so far assessing anti-SRLV CTL responses in goats. . 340 
Whether this CTL response is linked to a diminished viral load and/or to a delayed onset of arthritis, 341 
as preliminary observations under natural conditions, is currently being investigated. Besides CTL 342 
response, alternative mechanisms inducing protection based on resistance to superinfection due to 343 
viral interactions between vaccination and challenge strains (Berry et al., 2008) may be responsible 344 
for a potentially protective role of Roccaverano strain.  345 
In conclusion, the experimental infection of goats with the low pathogenic Roccaverano strain 346 
revealed a conventional immune response in terms of route of infection, time and extent of 347 
seroconversion and linfoproliferative responses, which were exclusively directed against 348 
homologous antigen. In the absence of antibody avidity maturation, CTL activity was mainly 349 
directed towards heterologous SRLV-infected MHC-I-restricted APCs, representing the sole 350 
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adaptive immune response which could be associated to protection against heterologous strain. 351 
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Figure captions 496 
Figure 1. Seroconversion against B and E P16-25 antigens at different time points post-inoculation 497 
(p.i.) with Roccaverano strain. Black circles and black squares: 498 
median absorbance versus B and E P16-25 antigens. Solid lines: absorbance inter quartile ranges. 499 
Dotted lines: absorbance ranges. Asterisks: Statistically significant differences between B and E 500 
absorbance. (Wilcoxon’s paired-sample test p <0.05). Gray-up triangles: samples only from 501 
experimental infection group. Gray-down triangles: samples only from pilot experiment group. 502 
 503 
Figure 2. Seroconversion against E SU5 antigen at different time points p.i.. Black squares: median 504 
absorbance. Solid lines: absorbance inter quartile ranges. Dotted lines: absorbance ranges. Gray-up 505 
triangles: samples only from experimental infection group. Gray-down triangles: samples only from 506 
pilot experiment group. 507 
 508 
Figure 3. T cell proliferation responses to GAG antigens derived from genotypes B and E. Results 509 
are expressed as the mean stimulation index (SI). Squares: mean reaction against E antigen (white: 510 
control group, black: immunized group). Circles: mean reaction against B antigen (white: control 511 
group, black: immunized group). Vertical bars: standard error of the mean. Comparison between 512 
reaction against E and B antigens in immunized groups: * Wilcoxon’s test p < 0.10, ** p < 0.05, 513 
*** p < 0.001. 514 
 515 
Figure 4. CTL activity generated 15 weeks post-inoculation (p.i.) with Roccaverano strain (n=8),  516 
in non-infected goats (n=9) and in the field-strain (subtype B1) infected grup (n=2). Amount of 517 
caspase 3 cleaved substrate (Ac-DEVD-AMC) per time unit is shown. Effector cells were 518 
stimulated with genotype B (grey bars)  or genotype E infected BDM (white bars). Vertical bars: 519 
standard error of the mean. 520 
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